168 related articles for article (PubMed ID: 35701182)
21. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.
Perche PO; Cook MK; Feldman SR
Ann Pharmacother; 2023 Jan; 57(1):86-98. PubMed ID: 35587593
[TBL] [Abstract][Full Text] [Related]
22. Abrocitinib for the treatment of atopic dermatitis.
Crowley EL; Nezamololama N; Papp K; Gooderham MJ
Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
[TBL] [Abstract][Full Text] [Related]
23. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
[TBL] [Abstract][Full Text] [Related]
24. Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.
Guttman-Yassky E; Facheris P; Gomez-Arias PJ; Del Duca E; Da Rosa JC; Weidinger S; Bissonnette R; Armstrong AW; Seneschal J; Eyerich K; Estrada YD; Bose SN; Xu D; Chen A; Tatulych S; Güler E; Chan G; Page KM; Kerkmann U
Allergy; 2024 May; 79(5):1258-1270. PubMed ID: 38108208
[TBL] [Abstract][Full Text] [Related]
25. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of abrocitinib for moderate-to-severe atopic dermatitis.
Labib A; Yosipovitch G
Expert Rev Clin Immunol; 2022 Nov; 18(11):1107-1118. PubMed ID: 36173402
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib.
Wojciechowski J; Malhotra BK; Wang X; Fostvedt L; Valdez H; Nicholas T
Br J Clin Pharmacol; 2022 Aug; 88(8):3856-3871. PubMed ID: 35342978
[TBL] [Abstract][Full Text] [Related]
28. Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Kim BS; Silverberg JI; Ständer S; Yosipovitch G; Simpson EL; DiBonaventura M; Kerkmann U; Farooqui SA; Biswas P; Valdez H; Cameron MC
Dermatitis; 2021 Oct; 32(1S):S39-S44. PubMed ID: 34175862
[TBL] [Abstract][Full Text] [Related]
29. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
30. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
Meher BR; Mohanty RR; Padhy BM
J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
[TBL] [Abstract][Full Text] [Related]
33. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
34. Reversible effects on female rat fertility with abrocitinib, a Janus kinase 1 inhibitor.
Bowman CJ; Campion SN; Catlin NR; Nowland WS; Stethem CM; Radi ZA; Cappon GD
Birth Defects Res; 2024 May; 116(5):e2345. PubMed ID: 38716582
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of alopecia universalis with abrocitinib: a case report.
Zhang J; Zuo YG
J Dermatolog Treat; 2023 Dec; 34(1):2242706. PubMed ID: 37526039
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
[TBL] [Abstract][Full Text] [Related]
39. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.
Jayaraman R; Pasha MK; Williams A; Goh KC; Ethirajulu K
Drug Metab Lett; 2015; 9(1):28-47. PubMed ID: 25600203
[TBL] [Abstract][Full Text] [Related]
40. Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism.
Bhamidipati R; Mujeeb S; Dravid PV; Khan AA; Singh SK; Rao YK; Mullangi R; Srinivas NR
Xenobiotica; 2005 Mar; 35(3):253-71. PubMed ID: 16019950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
